Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis

Zhang, Hongman; Shen, Jie; Yi, Lilan; Zhang, Wei; Luo, Peng; Zhang, Jian

doi:10.7150/jca.27368

Cited by 10 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Late-stage diagnosis and the limitations of classical therapies lead to a poor OS. Recent evidence suggests that immunotherapy is a powerful tool for lung cancer treatment (4)(5)(6). Therefore, the identification of novel biomarkers and promising immune-related therapeutic targets for lung cancer has become imperative in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma

Qiu

Guo

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Collagen type VI alpha 6 chain (COL6A6), a novel collagen, has been considered as a tumor suppressor and therapeutic target in several tumors. However, the functional role of COL6A6 in immune cell infiltration and prognostic value in lung adenocarcinoma (LUAD) remains unknown. Here, we evaluated COL6A6 expression and its impact on survival among LUAD patients from The Cancer Genome Atlas (TCGA) and several other databases. COL6A6 was downregulated in LUAD tissues compared to normal tissues at both mRNA and protein levels. COL6A6 expression was negatively associated with pathological stage, tumor stage, and lymph node metastasis. High COL6A6 expression was a favorable prognostic factor in LUAD. Next, we explored the associations between COL6A6 expression and immune cell infiltration. COL6A6 expression was positively associated with the infiltration of B cells, T cells, neutrophils and dendritic cells. Additionally, the immune cell infiltration levels were associated with COL6A6 gene copy number in LUAD. Consistently, gene set enrichment analysis showed that various immune pathways were enriched in the LUAD samples with high COL6A6 expression, including pathways related to T cell activation and T cell receptor signaling. The impacts of COL6A6 on immune activity were further assessed by enrichment analysis of 50 COL6A6-associated immunomodulators. Thereafter, using Cox regression, we identified a seven-gene risk prediction signature based on the COL6A6-associated immunomodulators. The resulting risk score was an independent prognostic predictor in LUAD. Receiver operating characteristic curve analysis confirmed that the seven-gene signature had good prognostic accuracy in the TCGA-LUAD cohort and a Gene Expression Omnibus dataset. Finally, we constructed a clinical nomogram to predict long-term survival probabilities, and calibration curves verified its accuracy. Our findings highlight that COL6A6 is involved in tumor immunity, suggesting COL6A6 may be a potential immunotherapeutic target in LUAD. The proposed seven-gene signature is a promising prognostic biomarker in LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma

Qiu

Guo

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In the exploratory analysis of phase II clinical trials of combined chemotherapy using ipilimumab, 13 it was found that patients with a high expression of antibodies before treatment may benefit from this regimen. A meta-analysis 14 indicated that ipilimumab improved the PFS (six months: RR=1.16, P=0.02; one year: RR=1.39, P=0.02) and six-month immunerelated PFS (irPFS) (RR=1.60, P=0.004) in 1084 SCLC patients. However, because of the addition of ipilimumab, immune-related toxicity was more obvious in the immunochemotherapy group.…”

Section: Discussionmentioning

confidence: 99%

<p>Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review</p>

Zhang

Wang

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

The incidence of lung neuroendocrine carcinomas, which originate from lung neuroendocrine cells, is 1.35/100,000, among which mixed neuroendocrine carcinomas are very rare. Because of the heterogeneity and significant differences in sensitivity to treatments, there is no effective treatment, and the prognosis is poor. In this article, we report the diagnosis and treatment of a case of mixed neuroendocrine carcinoma of the lung in our hospital. During the treatment, the patients had significant myelosuppression after initial chemotherapy, but benefited from oral chemotherapy consisting of a combination of capecitabine and temozolomide (CAPTEM). The report was approved by the affiliated Cancer Hospital of Shandong University.The patient was a 65-year-old male who developed paroxysmal cough without obvious causes in October 2013, with white sticky phlegm, accompanied by chest tightness and persistent back pain. On December 8, 2013, a chest CT showed a space-occupying lesion in the superior lobe of the left lung next to the mediastinum, which was located close to the aorta and showed significant enhancement on enhanced scan, with enlarged mediastinal lymph nodes in regions 1L, 2L and 5, suggesting metastasis. On December 6, 2013, a left lung mass biopsy was performed under CT guidance. The pathology (biopsy of the left upper lung mass) and immunohistochemistry results were consistent with neuroendocrine carcinoma and small-cell carcinoma. Immunohistochemical staining showed Syn+, CgA weak+, CK weak+, TTF-1+, broad-spectrum CK+, CK5/6-, P63 and Ki-67 (70-80%) (Figure 1). Tumour maker determination results were as follows: neuron-specific enolase (NSE) 40.00 ng/mL, cytokeratin-19 fragments (Cyfra21-1) 4.12 ng/mL and carcinoembryonic antigen (CEA) 28.10 ng/mL. There was no obvious abnormality found in bone electroconvulsive therapy (ECT) and cranial MRI examination. The patient was diagnosed with left lung neuroendocrine carcinoma (small-cell type),

show abstract

“…Increasing evidence suggest that immunotherapy is a sharp sword for cancers, especially for lung cancer. 3 Previous studies showed that LUAD tends to have several gene mutations, which includes TP53, KRAS, EGFR, BRAF, and ALK. [4][5][6] The somatic mutations in LUAD are well-studied and there are many targeted therapeutic strategies toward these mutations.…”

Section: Introductionmentioning

confidence: 99%

Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene‐expression–based retrospective study

Chen

Dong

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

Lung cancer is one of the fatal tumors. The tumor microenvironment plays a key role in regulating tumor progression. To figure out the role of tumor microenvironment in lung adenocarcinoma (LUAD), ESTIMATE algorithm was used to evaluate the immune scores in LUAD. Patients with low immune scores had a worse overall survival (OS) compared with high immune scores. Using RNA‐Seq data of 489 patients in The Cancer Genome Atlas (TCGA), differentially expressed genes (DEGs) were identified between high‐ and low‐immune score groups. Based on the DEGs, nine‐gene signature was constructed by the least absolute shrinkage and selection operator Cox regression model in TCGA set. The signature demonstrated significant prognostic value in both TCGA and Gene Expression Omnibus database. Multivariate Cox regression analyses indicated that nine‐genes signature was an independent prognostic factor. Subgroup analysis also revealed a robust prognostic ability of nine‐gene signature. A nomogram with a C‐index of 0.722 had a favorable power for predicting 3‐, 5‐, and 10‐year survival for clinical use by integrating nine‐gene signature and other clinical features. Co‐expression and functional enrichment analysis showed that nine‐gene signature was significantly associated with immune response and provided potential profound molecules for revealing the mechanism of tumor initiation and progression. In conclusion, we revealed the significance of immune infiltration and built a novel nine‐gene signature as a reliable prognostic factor for patients with LUAD.

show abstract

Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis

Cited by 10 publications

References 47 publications

Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma

Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma

<p>Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review</p>

Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene‐expression–based retrospective study

Contact Info

Product

Resources

About